150 related articles for article (PubMed ID: 36377344)
1. Plasma metabolomics for the assessment of the progression of non-small cell lung cancer.
Zhang Y; Cheng Y; Qin L; Liu Y; Huang S; Dai L; Tao J; Pan J; Su C; Zhang Y
Int J Biol Markers; 2023 Mar; 38(1):37-45. PubMed ID: 36377344
[TBL] [Abstract][Full Text] [Related]
2. Cortisol, cortisone, and 4-methoxyphenylacetic acid as potential plasma biomarkers for early detection of non-small cell lung cancer.
Xiang C; Jin S; Zhang J; Chen M; Xia Y; Shu Y; Guo R
Int J Biol Markers; 2018 Aug; 33(3):314-320. PubMed ID: 29896992
[TBL] [Abstract][Full Text] [Related]
3. Serum untargeted metabolomics reveal metabolic alteration of non-small cell lung cancer and refine disease detection.
Li J; Liu K; Ji Z; Wang Y; Yin T; Long T; Shen Y; Cheng L
Cancer Sci; 2023 Feb; 114(2):680-689. PubMed ID: 36310111
[TBL] [Abstract][Full Text] [Related]
4. Screening and identification of potential novel lipid biomarkers for non-small cell lung cancer using ultra-high performance liquid chromatography tandem mass spectrometry.
Han YS; Shi LY; Chen JX; Chen J; Li ZB; Lu QQ; Zhang SQ; Liu J; Yi WJ; Jiang TT; Li JC; Huang J
Anat Rec (Hoboken); 2022 May; 305(5):1087-1099. PubMed ID: 34347376
[TBL] [Abstract][Full Text] [Related]
5. [Lipid metabolomic analysis in exosomes of osteonecrosis of the femoral head based on ultra performance liquid chromatography-tandem mass spectrometry].
Guo M; Zhang J
Se Pu; 2022 Feb; 40(2):123-129. PubMed ID: 35080158
[TBL] [Abstract][Full Text] [Related]
6. [Screening of serum oxysterol biomarkers for colon cancer by liquid chromatography-tandem mass spectrometry].
Ma Z; Li Z; Wang H; Wang R; Han X
Se Pu; 2022 Jun; 40(6):541-546. PubMed ID: 35616199
[TBL] [Abstract][Full Text] [Related]
7. Detection and verification of coexisting diagnostic markers in plasma and serum of patients with non-small-cell lung cancer.
Yu M; Sun R; Zhao Y; Shao F; Zhu W; Aa J
Future Oncol; 2021 Nov; 17(32):4355-4369. PubMed ID: 34674559
[TBL] [Abstract][Full Text] [Related]
8. Combined metabolomics with transcriptomics reveals potential plasma biomarkers correlated with non-small-cell lung cancer proliferation through the Akt pathway.
Zheng J; Zheng Y; Li W; Zhi J; Huang X; Zhu W; Liu Z; Gong L
Clin Chim Acta; 2022 May; 530():66-73. PubMed ID: 35245482
[TBL] [Abstract][Full Text] [Related]
9. Changes in serum amino acid levels in non-small cell lung cancer: a case-control study in Chinese population.
Liu K; Li J; Long T; Wang Y; Yin T; Long J; Shen Y; Cheng L
PeerJ; 2022; 10():e13272. PubMed ID: 35469201
[TBL] [Abstract][Full Text] [Related]
10. Application of metabolomics by UHPLC-MS/MS in diagnostics and biomarker discovery of non-small cell lung cancer.
Liu Y; Wu J; Zhang K; Yang Q; Yang J; Cao R; Gu F; Liang J; Liu Y; Hu Y; Hong X; Zeng Y; Zheng Z; Liu L
Transl Cancer Res; 2019 Oct; 8(6):2371-2379. PubMed ID: 35116989
[TBL] [Abstract][Full Text] [Related]
11. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
12. Assessment of plasma amino acids, purines, tricarboxylic acid cycle metabolites, and lipids levels in NSCLC patients based on LC-MS/MS quantification.
Cang S; Liu R; Mu K; Tang Q; Cui H; Bi K; Zhang Y; Li Q
J Pharm Biomed Anal; 2022 Nov; 221():114990. PubMed ID: 36208488
[TBL] [Abstract][Full Text] [Related]
13. Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer.
Zhang YL; Zhang ZL; Zhu XB; Xu L; Lu P; Xu M; Liu WJ; Zhang XY; Yao HM; Ye XW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5251-5259. PubMed ID: 31298376
[TBL] [Abstract][Full Text] [Related]
14. Probing Folate-Responsive and Stage-Sensitive Metabolomics and Transcriptional Co-Expression Network Markers to Predict Prognosis of Non-Small Cell Lung Cancer Patients.
Lin YS; Chen YC; Chen TE; Cheng ML; Lynn KS; Shah P; Chen JS; Huang RS
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615660
[TBL] [Abstract][Full Text] [Related]
15. Integration of metabolomics and machine learning revealed tryptophan metabolites are sensitive biomarkers of pemetrexed efficacy in non-small cell lung cancer.
Sun R; Fei F; Wang M; Jiang J; Yang G; Yang N; Jin D; Xu Z; Cao B; Li J
Cancer Med; 2023 Sep; 12(18):19245-19259. PubMed ID: 37605514
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of disease staging and chemotherapeutic response in non-small cell lung cancer from patient tumor-derived metabolomic data.
Miller HA; Yin X; Smith SA; Hu X; Zhang X; Yan J; Miller DM; van Berkel VH; Frieboes HB
Lung Cancer; 2021 Jun; 156():20-30. PubMed ID: 33882406
[TBL] [Abstract][Full Text] [Related]
17. Serum Lipidomics Profiling to Identify Biomarkers for Non-Small Cell Lung Cancer.
Chen Y; Ma Z; Shen X; Li L; Zhong J; Min LS; Xu L; Li H; Zhang J; Dai L
Biomed Res Int; 2018; 2018():5276240. PubMed ID: 30175133
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of metabolite differences in skin between Clapp's Favorite and its mutant Red Clapp's Favorite through non-targeted metabolomics].
Mu H; Ci Z; Aisajan M; Liang Y; Liu X; DU X; Yu Q; Li Q; Li Y
Se Pu; 2021 Nov; 39(11):1203-1212. PubMed ID: 34677015
[TBL] [Abstract][Full Text] [Related]
19. Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
Shen J; Ye Y; Chang DW; Huang M; Heymach JV; Roth JA; Wu X; Zhao H
Lung Cancer; 2017 Dec; 114():70-78. PubMed ID: 29173770
[TBL] [Abstract][Full Text] [Related]
20. Urine metabolomics for assessing fertility-sparing treatment efficacy in endometrial cancer: a non-invasive approach using ultra-performance liquid chromatography mass spectrometry.
Chen J; Liu J; Cao D
BMC Womens Health; 2023 Nov; 23(1):583. PubMed ID: 37940929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
